Hands On Review,IV and SubQ doses up to 40mg/day

SS-31 peptide, also known by its investigational drug name elamipretide, is a synthetic peptide that has garnered significant attention for its potential to target and improve mitochondrial function. As research into its therapeutic applications expands, understanding SS-31 peptide dosing becomes crucial for individuals exploring its use. This article delves into the current understanding of SS-31 peptide dosing, drawing upon available clinical trial data and expert insights to provide a comprehensive overview.

The Role of SS-31 in Mitochondrial Health

Mitochondria, often referred to as the "powerhouses of the cell," are vital for energy production and cellular health. Mitochondrial dysfunction is implicated in a wide range of age-related conditions, metabolic disorders, and inflammatory processes. SS-31 is a mitochondrial targeted peptide designed to selectively accumulate within mitochondria, where it can help restore their normal function. This targeted action is believed to contribute to its potential benefits in areas such as improving mitochondrial function, reversing age-related mitochondrial dysfunction, and enhancing cellular energy and repair.

Exploring SS-31 Peptide Dosing Protocols

Determining the optimal dosage for SS-31 is an ongoing area of research, with various protocols emerging from preclinical studies and clinical trials. It's important to note that there is limited data on proper dosing and protocol of administration for SS-31 (elamipretide), and any use should ideally be under the supervision of a qualified healthcare professional.

Based on available information, common dosing strategies for SS-31 include:

* Initial Dosing and Tolerance Assessment: Some protocols suggest starting with a low dose, such as 5 mg daily for Weeks 1–2, to assess individual tolerance. This approach allows for gradual introduction of the peptide and monitoring for any adverse reactions.

* Standard Target Dosing: A frequently cited standard target dose is 10 mg daily by Week 3. This dose has been utilized in various clinical trials and represents a common clinical trial dose.

* Higher Doses in Clinical Trials: Human trials have explored IV and SubQ doses up to 40 mg/day. For instance, a Phase 3 trial, the MMPOWER-3 study, investigated 40 mg/day (s.c.) in patients with primary mitochondrial myopathy. Another study mentioned a dose of 40 mg/day as a safe and well-tolerable dose in human subjects, though it emphasizes that the dose can vary.

* Dosage Ranges for Specific Applications:

* For acute conditions, a dosage of 2 mg (0.2ml or 20 units) SQ has been noted.

* For general longevity/healthspan, a dose of 4 mg a day is suggested by some sources.

* For muscle recovery, metabolic, and performance-based studies, moderate doses (3 mg to 5 mg per day) are considered effective.

* For CKD (Chronic Kidney Disease) or general mitochondrial recovery, 1 to 5 milligrams a day is considered a good range.

* In preclinical research, elamipretide (SS-31) was administered at dosages of 10 mg/kg per day for 10 days in mice. Similarly, injection doses of 5 mg/kg and 10 mg/kg were used in studies evaluating neuroprotection.

Administration Routes and Considerations

SS-31 can be administered via different routes, including subcutaneous (SubQ) and intravenous (IV).

* Subcutaneous Administration: This is a common method of administration. For example, a 40 mg dose may involve drawing 2 mL from a 20 mg/mL concentration vial. Similarly, a 10 mg dose might require drawing 0.5 mL (50 units).

* Intravenous Infusion: SS-31 has also been reported as well-tolerated as an intravenous infusion. The dosage range for IV administration has been noted as 0.01 mg/kg/h to 0.25 mg/kg/h over 4 hr in humans, requiring dilution in 0.9% NS or D5W.

Important Dosing Parameters and Variations

When considering SS-31 peptide dosing, several factors can influence the appropriate amount:

* Indication: The specific health concern or goal for using SS-31 will significantly impact the dose. For instance, doses targeting organ damage might be higher than those for general healthspan.

* Individual Tolerance: As with any peptide therapy, individual responses can vary. Starting with a lower dose and gradually increasing it allows for personalized titration.

* Age and Weight: These factors can play a role in determining the appropriate dose, particularly in research settings or when calculating mg/kg dosages.

* Health History: Pre-existing health conditions and the use of other medications can